Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04444167 2024-04-25

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

Phase 1/2 Completed

59 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05842317 2024-02-09

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

Phase 1/2 Unknown

60 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03867370 2023-11-29

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Phase 1/2 Terminated

40 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT04443309 2023-03-29

Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC

Phase 1/2 Unknown

53 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT04911959 2023-02-06

Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC

Phase 1/2 Unknown

50 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT00946153 2019-02-01

Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)

Phase 1/2 Completed

66 enrolled 18 charts

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular

Clinical Trials

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC

Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC

Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)